Technical Analysis for ATHX - Athersys, Inc.

Grade Last Price % Change Price Change
grade D 1.55 1.31% 0.02
ATHX closed up 1.31 percent on Tuesday, March 19, 2019, on approximately normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
4 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical ATHX trend table...

Date Alert Name Type % Chg
Mar 19 20 DMA Support Bullish 0.00%
Mar 19 Crossed Above 50 DMA Bullish 0.00%
Mar 19 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 19 Bollinger Band Squeeze Range Contraction 0.00%
Mar 18 50 DMA Resistance Bearish 1.31%
Mar 18 Crossed Above 20 DMA Bullish 1.31%
Mar 18 Bollinger Band Squeeze Range Contraction 1.31%
Mar 18 Inside Day Range Contraction 1.31%
Mar 15 Fell Below 20 DMA Bearish 2.65%
Mar 15 Fell Below 50 DMA Bearish 2.65%

Older signals for ATHX ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine. The company's lead platform product, MultiStem, an allogeneic stem cell product, which was evaluated in two completed Phase I clinical trials and is under two ongoing Phase II clinical trials for treating a range of diseases and various application in the field of clinical regenerative medicine. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in identifying and developing novel pharmaceuticals to treat obesity; related metabolic conditions, such as diabetes; and neurological indications, including schizophrenia. It has collaboration agreement with Pfizer Inc. to develop and commercialize MultiStem to treat inflammatory bowel disease; and RTI Biologics, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market. The company was founded in 1995 and is based in Cleveland, Ohio.
Health Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Industry Diseases Pharmaceuticals Diabetes Pharmacy Drug Discovery Clinical Trial Obesity Schizophrenia Inflammatory Bowel Disease Regenerative Medicine Cardiovascular Disease Design Of Experiments Pfizer Mesoblast Orthopedic Applications
Is ATHX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Mar 19 What Makes Athersys (ATHX) a New Buy Stock
Mar 15 Edited Transcript of ATHX earnings conference call or presentation 14-Mar-19 8:30pm GMT
Mar 15 Athersys, Inc. (ATHX) CEO Gil Van Bokkelen on Q4 2018 Results - Earnings Call Transcript
Mar 14 Athersys Inc (ATHX) Q4 2018 Earnings Conference Call Transcript
Mar 14 Athersys Announces Financial Results for Fourth Quarter and Full Year 2018
Mar 14 Athersys, Inc. to Host Earnings Call
Mar 7 Athersys (ATHX) Q4 Earnings: What's in Store for the Stock?
Feb 27 Is Athersys, Inc.’s (NASDAQ:ATHX) CEO Paid Enough Relative To Peers?
Feb 14 Athersys to Host Year-End 2018 Financial Results Call
Jan 24 Athersys' (ATHX) MultiStem Cell Therapy Succeeds in Study
See more ATHX news...
Indicators
Indicator Value
52 Week High 3.09
52 Week Low 1.36
Average Volume 578,327
200-Day Moving Average 1.8745
50-Day Moving Average 1.5336
20-Day Moving Average 1.528
10-Day Moving Average 1.527
Average True Range 0.0776
ADX 16.88
+DI 18.2984
-DI 12.9464
Chandelier Exit (Long, 3 ATRs ) 1.4472
Chandelier Exit (Short, 3 ATRs ) 1.6928
Upper Bollinger Band 1.5977
Lower Bollinger Band 1.4583
Percent B (%b) 0.66
BandWidth 9.123037
MACD Line -0.0018
MACD Signal Line -0.0048
MACD Histogram 0.003
Fundamentals Value
Market Cap 176.56 Million
Num Shares 114 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -5.96
Price-to-Sales 61.05
Price-to-Book 8.00
PEG Ratio -0.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.64
Resistance 3 (R3) 1.63 1.60 1.63
Resistance 2 (R2) 1.60 1.57 1.60 1.62
Resistance 1 (R1) 1.57 1.56 1.59 1.58 1.61
Pivot Point 1.54 1.54 1.54 1.54 1.54
Support 1 (S1) 1.51 1.51 1.53 1.52 1.49
Support 2 (S2) 1.48 1.50 1.48 1.48
Support 3 (S3) 1.45 1.48 1.48
Support 4 (S4) 1.46